Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 13, 2020

BUY
$13.19 - $16.66 $1.32 Million - $1.67 Million
100,000 Added 11.11%
1,000,000 $14.7 Million
Q2 2020

Aug 14, 2020

BUY
$14.12 - $18.33 $2.12 Million - $2.75 Million
150,000 Added 20.0%
900,000 $14.6 Million
Q1 2020

May 14, 2020

BUY
$11.34 - $21.46 $8.51 Million - $16.1 Million
750,000 New
750,000 $10.9 Million

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.15B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Artal Group S.A. Portfolio

Follow Artal Group S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.